Joule Biotechnologies Elects Graham Allison to Board of Directors

CAMBRIDGE, Mass.--(Business Wire)--
Joule Biotechnologies, Inc., an innovative bioengineering startup developing
game-changing alternative energy solutions, today announced the election of
Graham Allison to its board of directors.

Dr. Allison is the Douglas Dillon professor and Director of the Belfer Center
for Science and International Affairs at Harvard University`s John F. Kennedy
School of Government. As "founding dean" he built the leading school of public
policy in the world. He served as Assistant Secretary of Defense in the first
Clinton Administration and as Special Advisor to the Secretary of Defense under
President Reagan. A recognized authority on US national security policy, he has
served on the Defense Policy Board for Secretaries Weinberger, Carlucci, Cheney,
Aspin, Perry and Cohen.

Dr. Allison`s background in the energy sector includes service as a director of
the Getty Oil Company and Belco Oil and Gas, a member of the advisory boards of
Hydro-Quebec and the International Energy Corporation, and Executive Director of
the International Atomic Energy Agency`s Commission of Eminent Persons.

"I am pleased to join the board of a company that is inventing and delivering an
entirely new category of clean, renewable fuel," said Dr. Allison. "Joule`s
proprietary technologies, engineering systems, business model, research and
management team are compelling. I look forward to working with the other
directors of the board as the company moves from the lab to industrial
production over the next several years."

"As Joule ramps up from successful laboratory scale to full production, we
continually seek the strategic guidance of our world-class board of directors,
whose considerable strengths range from business and entrepreneurship to life
sciences and innovation," said Bill Sims, President and CEO, Joule
Biotechnologies. "We are very pleased to welcome Graham, whose proven leadership
and knowledge of the energy sector will complement the board`s composition."

In addition to Dr. Allison and Mr. Sims, Joule`s board comprises the following
members:

* Noubar Afeyan, PhD, Chairman and founder of Joule

Dr. Afeyan is Managing Partner and CEO of Flagship Ventures, a firm that manages
over $600 million in early-stage funds across the sectors of Therapeutics, Life
Science, and BioEnergy/Cleantech. A technologist, entrepreneur and venture
capitalist, Dr. Afeyan has co-founded and helped build over 20 successful life
science and technology start-ups during the past two decades. He was a member of
the founding team, director and investor in successful ventures including
Chemgenics Pharmaceuticals, Color Kinetics, Antigenics, EXACT Sciences and
Adnexus Therapeutics. In addition to Joule, he is a director and co-founder of
Affinnova, BG Medicine, Ensemble Discovery and Genstruct, among others.

* David Berry, MD, PhD, Founder of Joule

Dr. Berry is a Partner at Flagship Ventures, where he focuses on investing in
and founding early-stage life science and cleantech ventures. His work has led
to 11 peer-reviewed publications, over 50 patents and applications, and over 25
awards and honors including the prestigious Lemelson-MIT Student Prize in 2005
for invention and innovation. He was named Innovator of the Year by Technology
Review in its 2007 TR35 list of the world`s top 35 innovators under the age of
35.

* Stelios Papadopoulos, PhD

Dr. Papadopoulos is co-founder and chairman of Exelixis, a development-stage
biotech company focused on novel small molecule therapeutics for the treatment
of cancer and other serious diseases. He retired as Vice Chairman of Cowen & Co.
in August 2006, where he focused on the biotechnology and pharmaceutical
sectors. He previously spent 13 years as an investment banker at PaineWebber,
where he was most recently Chairman of PaineWebber Development Corp., a
subsidiary focusing on biotechnology. He is a co-founder and board member of
Anadys Pharmaceuticals and Cellzome, and also serves on the boards of BG
Medicine, Regulus Therapeutics and Biogen Idec.

About Joule Biotechnologies

Joule Biotechnologies, Inc. is tackling the global energy crisis with a
game-changing, renewable alternative to transportation fuels. Its patent-pending
Helioculture™ technology surpasses the limitations of biomass-derived fuel
approaches by using sunlight to convert CO2 directly into Joule™ liquid energy.
This direct-to-fuel conversion requires no fresh water and minimal
non-agricultural land, avoids costly intermediaries and processing, and finally
enables the scale, unlimited quantities and pricing required for energy
independence. Founded in 2007 by Flagship Ventures, Joule is privately held and
headquartered in Cambridge, Massachusetts. Additional information is available
at www.joulebio.com.

Schwartz Communications
Dan Borgasano, 781-684-6660
joule@schwartz-pr.com

Copyright Business Wire 2009